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Abstract
A DNA fragment containing the defective virulence gene(s) in the live oral
vaccine candidate Salmonella typhimurium SR-11 Fad· was isolated. Genomic DNA
fragments from the vaccine candidate, constructed by TnlOd::cam transposon
mutagenesis, were probed with the 1.4 Kbp chloramphenicol resistance gene contained in
TnlOd::cam and analyzed by Southern hybridization. Two of the fragments, an 8.0 Kbp
Hind III fragment and a 4.5 Kbp Pst I :fragment, were isolated, cloned into E. coli HB 101,

and mapped. The Pst I fragment, containing approximately 2.9 Kbp of flanking genomic
DNA, was subcloned into the sequencing vector pBluescript II SK + (Stratagene, La
Jolla, CA) and mapped.

11

Acknowledgement

* Dr. Paul S. Cohen
*Dr. Richard E. Koske
*Dr. David R. Nelson
*Dr. Alison Roberts
* Dr. David C. Laux

* Maryjane Utley
* Paul W. Johnson
* Carolyn Lunt
* The Nelson Lab
* The Norris Lab
* Michael Bono
* Aimee Hebert
* Ian Lodovice

iii

Preface
This research is presented here in the standard format for thesis.

IV

Contents
Abstract. .............................................................................................................................. .ii
Acknowledginent............................................................................................................... .iii
Preface............................................................................................................................... .iv
Contents............................................................................................................................... v
List of Tables....................................................................................................................vii
List ofFigures...................................................................................................................viii
Introduction.......................................................................................................................... 1
The Vaccine Candidate: Salmonella typhimurium SR-11 Fad-...........................................2
Materials and Methods .........................................................................................................4
Agarose gel electrophoresis.....................................................................................4
Bacterial strains........................................................................................................ 4
Calf intestinal alkaline phosphatase..................-...................................................... .4
DIG-labeled probes..................................................................................................4
Endonuclease digests ...............................................................................................5
Incubation of bacterial cultures and plates............................................................... 5
Isolation of DNA..................................................................................................... 5
Ligase reactions .....................................................................................................10
Media and antibiotics ............................................................................................. 10

v

Southern blotting.................................................................................................... 10
Transformations ..................................................................................................... 12
Vectors ................................................................................................................... 13
Results ................................................................................................................................ 15
Isolation of the chloramphenicol resistance cassette............................................. 15
Southern blot of Salmonella typhimurium SR-11 Fad-......................................... 16
Cloning of the Hind III and Pst I fragments of Salmonella typhimurium
SR-11 Fad- genomic DNA..................................................................................... 17
Cloning the 4.5 Kbp Pst I fragment using a sequencing vector............................. 19
Discussion.......................................................................................................................... 21
Tables.................................................................................................................................24
Figures................................................................................................................................ 25
References .................................................................... :..................................................... 38
Bibliography.......................................................................................................................41

vi

List of Tables
Bacterial strains.................................................................................................................. 24

vii

List of Figures
The unique Bam ID, Eco Rl, Hind III, and Pst I restriction enzyme sites in
the cloning vector pBR322 ................................................................................................ 25
The construction of pJHA I ................................................................................................26
The interruption of the tetracycline resistance gene in the plasmid pJHA 1....................... 27
Agarose (0.9%) gel analysis of the plasmid pJHAl.. ........................................................28
The plasmid pJHAl mapped with the restriction enzymes BamH I and EcoR 1.. ............. 29
Unique restriction enzyme sites in the plasmid pJHAl.. ................................................. .30
Southern hybridization analysis of SR-11 genomic DNA............................................... .31
Agarose (0.5%) gel analysis of the plasmid pJHA6 ......................................................... .32
Agarose (0.7%) gel analysis of the plasmid pJHA6 ......................................................... .33
The plasmid pJHA6 mapped with BamH I, EcoR I, and Pst I ......................................... .34
Map of the sequencing vector pBluescript II SK+ ..... :.................................................... .35
Agarose (0.7%) gel analysis of the plasmid pJHA7 ......................................................... .36
The plasmid pJHA7 mapped with BamH I, EcoR I, and Pst 1.. ........................................ .37

viii

Introduction
Poultry production is reduced significantly by Salmonella bacteria. The U.S.
poultry industry hatches approximately 7.5 billion eggs annually in incubation facilities,
and nearly $77 million is lost to the poultry industry each year due to Salmonella
outbreaks in poultry farms (1 ). The health care costs associated with human
salmonellosis caused by eating contaminated eggs and poultry is estimated at $4 billion
annually (1 ). Vaccination of chickens against Salmonella would both reduce losses to the
poultry industry and the poultry-associated human salmonellosis.
Typhoid fever, an infectious disease caused by the bacterium Salmonella typhi,
remains a serious public health problem in developing countries causing an estimated
600,000 deaths annually (2). Two Salmonella typhi vaccines, the live oral S. typhi Ty21 a
and a vaccine based on the Vi polysaccharide capsule of S. typhi, currently are licensed
in several countries (3). Each of these vaccines, while effective, still suffers from
drawbacks such as fevers after administration, incomplete protection, and a loss of
protection with time (3). Therefore biotechnology is being used to develop new
attenuated S. typhi live oral vaccines (3).
Live oral vaccines, based on deletions into genes necessary for Salmonella
pathogenesis, have shown great promise (4, 5). For example, the live oral S. typhimurium
~cya

(adenylate cyclase) ~crp (cAMP receptor protein) vaccine is based on deletions in a

Salmonella global regulatory system and is effective in animals and humans (4, 5).
Another S. typhimurium live oral vaccine, avirulent and immunogenic in mice and cattle,
is based on aro (aromatic compounds) deletions; this strain is auxotrophic for p-

aminobenzoic acid and 2,3-dihydroxybenzoate which are unavailable in mammalian cells
(6, 7). In addition, Salmonella strains containing deletions in genes of the phoP-phoQ
regulon (regulation of virulence) are effective mouse and human vaccines (8, 9).
The use of attenuated Salmonella strains as live vaccines is a safe and effective
means of inducing significant humoral and secretory antibody responses in animal
species: humans, cattle, sheep, rabbits, fowl, and mice (10). Live Salmonella invade the
Peyer's patches, where they present their numerous antigens directly to the T and B
lymphocytes of the mucosal-associated lymphoid tissues (10). This elicits the mucosal
immune system to produce antigen-specific immune responses (10). Because of the
significant humoral and secretory antibody responses, live attenuated Salmonella strains
show great promise for carriers of antigenic determinants from other pathogenic
microorganisms (10).
The Vaccine Candidate: Salmonella typhimurium SR-11 Fad·. The live oral
vaccine candidate, Salmonella typhimurium SR-11 Fad·, was constructed by TnlOd::cam
transposon mutagenesis of the SR-11 parent strain (11). The mutant strain was selected
for its inability to catabolize oleate and citrate as sole carbon sources (11 ). It was
phenotypically designated Fad- (Fatty acid) for its inability to catabolize fatty acids as a
sole carbon source (11 ). The SR-11 Fad- strain also was unable to utilize acetate and
isocitrate as carbon sources, but could utilize glucose, glycerol, pyruvate, and succinate as
sole carbon sources (11 ).

Salmonella typhimurium SR-11 Fad·, administered peroraly, was completely
avirulent in BALB/c mice at a dose as high as 109 colony forming units (cfu) (11). In

2

contrast, the SR-11 parent strain proved lethal at doses of greater than 104 cfu (11 ). The
vaccine candidate also was found to be protective in BALB/c mice (11) as well as
avirulent and protective in chickens (Dr. Paul S. Cohen: personal communication). A
single oral dose of 107 SR-11 Fad· cells protected BALB/c mice against a lethal dose of
109 cells of the virulent SR-11 Salmonella typhimurium parent strain (11).

In order for a vaccine to be useful, it must be safe. Therefore is should not
contain antibiotic resistance genes. Since the SR-11 Fad· vaccine candidate was
constructed by TnJOd::cam transposon mutagenesis (11), it contains a chloramphenicol
resistance gene. This chloramphenicol cassette is interrupting a virulence gene(s) and is
blocking the expression of that virulence gene(s). Further development of this vaccine
candidate required the isolation of this interrupted virulence gene(s). The virulence
gene(s) and the chloramphenicol resistance cassette can then be permanently deleted,
yielding a safer live oral vaccine candidate.
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Materials and Methods
Agarose gel electrophoresis. Agarose gels were made with concentrations
between 0.50% and 0.90% of electrophoresis grade agarose (Fisher Scientific, Fair Lawn,
NJ) in TAE buffer (40 mM Tris-acetate; 1.0 mM EDTA, 5 Prime~ 3 Prime, Inc.,
Boulder, CO) and ethidium bromide (final concentration: 0.2-0.4 µg/ml; Sigma Chemical
Co., St. Louis, MO) (12). Several DNA standard markers were used: phage lambda cut
with Hind III (Gibco BRL, Gaithersburg, MD) and 1 Kbp DNA ladders (Gibco BRL,
Gaithersburg, MD and Promega Corporation, Madison, WI).
Bacterial strains. See Table 1.
Calf intestinal alkaline phosphatase. Calf intestinal alkaline phosphatase
(CIAP) (Promega Corporation, Madison, WI) was employed for the hydrolysis of 5'phosphate groups from vector DNA, following incubation with a restriction enzyme.
Three successive CIAP reactions, following the manufacturer's protocol, were performed
on vectors prior to ligation to an insert.
DIG-labeled probe. A DIG-labeled (digoxigenin) probe was made from the 1.4
Kbp chloramphenicol cassette using A DIG High Prime DNA Labeling & Detection
Starter Kit II (Boehringer-Mannheim, Germany): 750 ng of template DNA
(chloramphenicol cassette) was denatured by boiling for 10 minutes and quickly cooled in
an ice/ethanol bath; the now single-stranded template DNA was added to a labeling
reaction mixture of deoxynucleoside triphosphates (dATP, dGTP, dCTP, dTTP and DIGdUTP) and the Kienow fragment of DNA polymerase III; labeling of the template
occurred, in this DNA synthesis reaction, by the random incorporation ofDIG-dUTP (a
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steroid hapten covalently bound to deoxycytidine triphosphate) over a 25 hour period at
37°C. The labeling reaction was stopped by heat inactivation at 65°C for 10 minutes.

Endonuclease digests. The restriction endonucleases, Bam HI, Eco RI, Hind III,
Pst I, Pvu II, and Xho I were purchased from Gibco BRL (Gaithersburg, MD) and/or
Promega Corporation (Madison, WI). The manufacturer's protocols for restriction
endonuclease digestions were modified for volumes of20-50 µl using nuclease-free,
deionized, distilled water (Sigma Chemical Co., St. Louis, MO), and DNA was digested
overnight with an excess of enzyme (>5U/µg DNA).

Incubation of bacterial cultures and plates. All liquid bacterial cultures, except
where noted, were grown overnight at 37°C with aeration in the appropriate antibiotic.
All plates inoculated with bacteria, except where noted, were incubated at 37°C for 12-18
hours.

Isolation of DNA. (Note: volume of reagents used and/or centrifugation speed
and time varied according to the initial volume of the bacterial cultures and/or bacterial
stain.) Genomic DNA was isolated.by a modified protocol from Current Protocols in

Molecular Biology (13). Bacterial cells from an overnight culture were pelleted by
centrifugation, resuspended in TE Buffer, gently lysed with sodium dodecyl sulfate (SOS)
(BioRad Laboratories, Richmond, CA), and incubated at 37°C for one hour in proteinase
K (Sigma Chemical Co., St. Louis, MO) to degrade the proteins.
Hexadecyltrimethylammonium bromide (10% CTAB in 0.7 M NaCl, Sigma Chemical
Co., St. Louis, MO) and NaCl was added to the lysate and incubated at 65°C for 15
minutes: the CTAB solution complexes with denatured protein and polysaccharides; the
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salt neutralizes macromolecules. An emulsion was formed by the addition of an equal
volume of chloroform/isoamyl (24: 1) (Sigma Chemical Co., St. Louis, MO) to the lysate.
The aqueous phase, containing the DNA, was extracted after centrifugation leaving
behind an organic phase of cell wall debris, denatured protein, and polysaccharides
complexed to CTAB. A second extraction with phenol/chloroform/isoamyl (25:24:1)
(Sigma Chemical Co., St. Louis, MO), removed residual CTAB precipitate. The DNA
was precipitated in 100% isopropanol (Sigma Chemical Co., St. Louis, MO) and pelleted
by centrifugation. The DNA pellet was rinsed in 70% ethanol to remove excess salt,
lyophilized, and resuspended in TE buffer. Incubation (37°C for greater than 1 hour) of
the genomic DNA in RNase A (Sigma Chemical Co., St. Louis, MO) degraded most of
the contaminating RNA. The DNA underwent a final phenol/chloroform/isoamyl
extraction to remove the RNase A and any residual proteins. After precipitation in 100%
ethanol, the genomic DNA was ready for manipulation.
Genomic DNA also was isolated by using the G NOME® genomic DNA isolation
kit (BIO 101, Vista, CA). The protocol from the manufacturer was modified by
increasing the initial volume of overnight liquid bacterial cell culture to 10 ml per
miniprep. The kit used a "Cell Suspension Solution," "RNase Mixx," "Cell
Lysis/Denaturing Solution," "Protease Mixx," and "Salt-Out Mixture" of unspecified
composition and replaced the chloroform steps of the standard protocol (13) with
incubation at 4°C followed by centrifugation. A final precipitation of the genomic DNA
in 100% ethanol completed the manufacturer's protocol. Genomic DNA isolated by the
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kit contained less RNA and protein contaminants than genomic DNA isolated by the
standard protocol (13).
Quantities of plasmid DNA greater than 10 µg were isolated by modified alkaline
lysis (14). A minimum of 100 ml of bacterial cells from an overnight liquid culture were
pelleted by centrifugation and resuspended in GTE Buffer (50 mM glucose; 10 mM
EDTA [ethylenediaminetetraacetic acid]; 25 mM Tris-HCl
[Tris[hydroxymethyl]aminomethane hydrochloride], Fisher Scientific, Fair Lawn, NJ).
The resuspended cells were added to a lysis solution, containing 0.2 N NaOH (Sigma
Chemical Co., St. Louis, MO) and 1.0% SDS (wt/vol), and incubated on ice for IO
minutes. An appropriate volume of potassium acetate solution (5 M KOAc, pH 4.8) was
mixed into the cell lysate and centrifuged. The supernatant, containing the plasmid DNA,
was extracted with phenol/chloroform/isoamyl alcohol and precipitated in 100%
isopropanol at -20°C for 30 minutes. The plasmid DNA was pelleted by centrifugation,
rinsed in 70% ethanol to remove excess salt, lyophilized, and resuspended in TE buffer.
Incubation (37°C for greater than 1 hour) of the plasmid DNA in RNase A degraded most
of the contaminating RNA. The plasmid DNA underwent a final
phenol/chloroform/isoamyl extraction to remove the RNase A and any residual proteins.
After a final concentration by precipitation in 100% ethanol, the plasmid DNA was ready
for manipulation.
Quantities of plasmid DNA less than 10 µg were isolated by Wizard™ Plus
Minipreps DNA Purification Systems (Promega Corporation, Madison, WI). The
protocol from the manufacturer was modified by increasing the initial volume of
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overnight liquid bacterial cell culture to 25 ml per miniprep. The bacterial cells were
pelleted by centrifugation and resuspended in Cell Resuspension Solution (50 mM Tris,
pH 7.5; 10 mM EDTA; 100 µg/ml RNase A). Cell Lysis Solution (0.2 N NaOH; 1.0%
SDS) was added to the resuspended cells, mixed by inversion of the microcentrifuge
tubes, and incubated at room temperature for 5 minutes. Neutralization Solution (1.32 M
KOAc) was mixed into the cell lysate and centrifuged. The supernatant, containing the
plasmid DNA, was pipetted into a 3 ml syringe (Becton Dickenson and Co., Franklin
Lakes, NJ) attached to a Wizard™ Minicolumn. Wizard™ DNA Purification Resin was
added to the lysate and plunged through the minicolumn. The minicolumn was rinsed
with Column Wash Solution (80 mM KOAc; 8.3 mM Tris-HCl, pH 7.5; 40 µM EDTA;
55% ethanol), removed from the syringe and dried by centrifugation. Plasmid DNA was
eluted off the minicolumn by the addition of TE buffer and centrifugation. The plasmid
DNA was then ready for manipulation.
DNA was purified, when necessary, by extraction with
phenol/chloroform/isoamyl alcohol (15). Phase Lock Gel™ (5

Prime~

3 Prime, Inc.,

Boulder, CO) microcentrifuge tubes were used during the extraction process according to
the manufacturer's protocol: an equal volume of DNA sample (genomic or plasmid) and
phenol/chloroform/isoamyl alcohol were added to a Phase Lock Gel™ microcentrifuge
tube, mixed, and centrifuged (14,000 x g) for two minutes. A thick density barrier was
formed between the upper aqueous phase, containing the DNA, and the protein-laden
interface and the lower organic phase. The upper aqueous phase was then simply poured
off into sterile microcentrifuge tubes. A second extraction of the trapped organic phase
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with TE buffer and phenol/chlorofonn/isoamyl alcohol removed any remaining DNA.
The DNA samples were pooled, concentrated by ethanol precipitation, lyophilized, and
resuspended in an appropriate volume of TE buffer.
DNA was concentrated, when necessary by ethanol precipitation (15).
GenElute™ (Supelco, Bellefonte, PA) LPA (linear polyacrylamide DNA carrier) was
used in all ethanol precipitations of plasmid DNA. The protocol from the manufacturer
was modified by increasing the sodium acetate (Sigma Chemical Co., St. Louis, MO)
concentration to 0.3 M to facilitate a more complete precipitation of the DNA in 100%
ethanol (Quantum Chemical CO, Tuscola, IL). Precipitated DNA was pelleted by
centrifugation (12,000 x g), lyophilized, and resuspended in TE buffer (I 0 mM Tris-Cl;
1.0 mM EDTA, 5 Prime~ 3 Prime, Inc., Boulder, CO). DNA was frozen at -20°C for
short-term storage and -78°C for long-term storage.
Concentrations of DNA were estimated by ethidium bromide dot quantitation
(16). Sample DNA, in a series of dilutions in TE Buffer and ethidium bromide (1.0
µg/ml final concentration), was spotted onto Parafilm®-M (American Can Company,
Greenwich, CT) and viewed on a ultra-violet transilluminator. A series of standards,
lambda DNA cut with Hind III (Gibco BRL, Gaithersburg, MD), was spotted above the
sample DNA. Comparison of the fluorescence of the sample to these standards provided
an estimate of the DNA concentration in the sample (16).
DNA was also recovered from agarose gels. Bands of electrophoresed genomic
or plasmid DNA were cut from agarose gels and added to GenElute™ Minus EtBr Spin
Columns (Supelco, Bellefonte, PA) prewashed in TE Buffer. The columns were inserted
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onto microcentrifuge tubes and centrifuged (12,000 x g) for 10 minutes. The columns
retained the agarose and ethidium bromide while the DNA was eluted by the TE buffer.
The DNA was then concentrated by ethanol precipitation.
Ligase reactions. T4 DNA ligase (Promega Corporation, Madison, WI) reactions
were performed according to the manufacturers protocol for greater than 12 hours at
l 6°C. T4 DNA ligase catalyzed the formation of a 3' to 5' phosphodiester bonds between
the 3'-hydroxyl group of one restriction fragment and the 5'-phosphate group of another
restriction fragment while their sticky ends are transiently base-paired (17).
Media and antibiotics. Luria broth (Lennox formulation: 5g NaCl IL, Sigma
Chemical Co., St. Louis, MO; 10 g tryptone IL, Difeo Laboratories, Detroit, MI; 5g yeast
extract IL, Difeo Laboratories, Detroit, MI; pH 7.5) and Luria agar plates (Lennox
formulation for Luria broth plus 15 g Bacto agar IL, Difeo Laboratories, Detroit, MI; pH
7.5) were used exclusively. Antibiotics were purchased from Sigma Chemical Co. (St.
Louis, MO) and added to the media at a final concentration as follows: 100 µg/ml
ampicillin; 30 µg/ml chloramphenicol; 50 µg/ml nalidiXic acid; 100 µg/ml streptomycin
sulfate; 10 µg/ml tetracycline hydrochloride. MacConkey agar (Difeo Laboratories,
Detroit, MI) and XLD agar (Difeo Laboratories, Detroit, MI) were used to characterize
initial strains and all transformants.
Southern blotting. DNA, digested with restriction enzymes, was electrophoresed
in a 0.85% agarose gel and photographed on an ultra-violet transilluminator (18). The
DNA was partially depurinated by gently shaking the agarose gel in 0.25 M HCl bath for
30 minut~s (19). The partial depurination cleaved DNA strands into fragments 1 to 2 Kb
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in length improving their mobility in the gel (19). The gel was rinsed with distilled water
and bathed in 0.4 M NaOH on an orbital shaker for 20 minutes. The DNA within the gel
was denatured at this step yielding single-stranded DNA (19). The single-stranded DNA
was then transferred overnight to a Magna Charge Nylon (Micron Separations, Inc.,
Westboro, MA) membrane (positively-charged) by upward capillary action using 0.4 M
NaOH as the transfer buffer (19). The negatively-charged DNA was immobilized on the
positively-charged nylon membrane during the transfer. The membrane was rinsed in 2x
SSC (0.3 M NaCl; 30 mM sodium citrate; pH 7.0; 5 Prime-+ 3 Prime, Inc., Boulder, CO)
twice to remove excess salt and agarose fragments (19).
A DIG High Prime DNA Labeling & Detection Starter Kit II (BoehringerMannheim, Germany) was used to further hybridize and develop the blot. The DIGlabeled 1.4 Kbp chloramphenicol cassette probe, denatured by boiling for 5 minutes and
quickly cooled in an ice/ethanol bath, was diluted in prewarmed standard hybridization
buffer (5x SSC; 0.1 % [wt/vol] N-lauroylsarcosine; 0.02% [wt/vol] SDS; 1% [vol/vol]
Blocking reagent) to a final concentration of 15 ng/ml.. The probe was hybridized to the
membrane for 12.5 hours at 68°C with gentle agitation. At this point, the single-stranded
DNA probe in solution hybridized to homologous single-stranded DNA bound to the
membrane. The membrane was then rinsed in post-hybridization solutions: twice with
2x SSC, 0.1 % SDS at room temperature and twice with 0.1 % (vol/vol) SSC, 0.1 %
(wt/vol) SDS at 68°C with gentle agitation. The post hybridization washes (stringency
washes) removed any non-specifically bound probe from the membrane.
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To detect the probe, the membrane was rinsed for 5 minutes in washing buffer
(0.1 M maleic acid, Sigma Chemical Co., St. Louis, MO; 0.15 M NaCl; 0.3% [vol/vol]
Tween 20®, Bio-Rad Laboratories, Hercules, CA; pH 7.5). The membrane was then
incubated for 30 minutes in blocking solution (0.1 M maleic acid; 0.15 M NaCl; 10%
[vol/vol] Blocking reagent). The membrane was then incubated for 30 minutes in antiDIG-AP conjugate antibodies (anti-digoxigenin Fab fragments conjugated to alkaline
phosphatase) diluted to 75 mU/ml in blocking solution. The anti-DIG-AP conjugate
antibodies bound the DIG-labeled 1.4 Kbp chloramphenicol cassette probe via the hapten
digoxigenin coupled to dUTP. Non-specific binding of the antibodies to the membrane
was decreased by the blocking solution. The membrane was then washed twice for 15
minutes in washing buffer and equilibrated for 5 minutes in detection buffer (0.1 M TrisHCl; 0.1 M NaCl; 50 mM MgCh; pH 9.5). The substrate CSPD® was added to the
membrane in a development folder and incubated at room temperature for 5 minutes.
Enzymatic dephosphorylation of the substrate CSPD® by alkaline phosphatase (anti-DIGAP conjugate antibodies bound to the DIG-labeled probe) emitted light at a maximum
wavelength of 4 77 run. The light emissions were recorded on Hyperfilm-ECL High
Performance Chemiluminescence Film (Amersham Life Science, Buckinghamshire,
England) with exposure times ranging from 30 seconds to 5 minutes.

Transformations. Competent recipient cells are required for high-efficiency
transformation by electroporation (20). Escherichia coli HBlOl competent recipient cells
were prepared for all transformations according to modified protocol from Current
Protocols in Molecular Biology (20). An overnight culture of Escherichia coli HBlOl
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cells were grown in Luria broth containing 100 µg/ml streptomycin sulfate; the fresh
overnight culture was diluted (1: 100) into Luria broth lacking the antibiotic and grown to
an optical density (absorbance @600 nm) of 0.5 to 1.0. The cells were chilled on ice and
pelleted by centrifugation (4000 x g) for 15 minutes in a cold rotor. The supernatant was
poured off and the cells were resuspended in the same volume of cold, sterile, distilled,
deionized water (ddiH20). The bacterial cells were pelleted by centrifugation, washed
again in sterile ddiH20, and washed once in 20 ml of 10% glycerol (vol/vol) (Sigma
Chemical Co., St. Louis, MO). The washed cells were resuspended in 10% glycerol
(vol/vol) to a final concentration of approximately 1010 cells/ml. These competent
recipient cells were used immediately and/or frozen at -78°C for up to 6 months.
Electroporation with high voltage was utilized to introduce plasmid DNA into the
competent recipient cells (20). Each transformation contained 40 µl of chilled competent
recipient cells and 1-2 µl of heat-inactivated ligase reaction. These were electroporated in
0.2 cm electrode gap cuvettes (Bio-Rad Laboratories, Hercules, CA) using a Bio-Rad
Pulse Controller and Bio-Rad Gene Pulser (Bio-Rad Laboratories, Hercules, CA) at 2.5
kV, 25µF, and 2000. Time constants ranged between 4.4 msec to 4.8 msec. The
electroporated cells were then incubated, shaking, for 1 hour at 3 7°C in Luria broth.
During this time, CIAP-treated plasmids (when used) were repaired as they replicated
within the cell. After incubation, 200 µl aliquots of the transformation mixture were
plated onto Luria agar containing the appropriate antibiotic.
Vectors. The vector, pBR322 (Figure 1), was isolated from Escherichia coli
HBlOl (pBR322). The vector, pBluescript II SK(+), was purchased from Stratagene (La
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Jolla, CA).
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Results
Isolation of the chloramphenicol resistance cassette. A live oral vaccine
candidate, Salmonella typhimurium SR-11 Fad·, had been constructed previously by
TnlOd::cam transposon mutagenesis of the SR-11 parent strain (11). The location of the

inserted chloramphenicol cassette within the chromosome of SR-11 Fad· was unknown.
As a first step in determining the location of the chloramphenicol cassette inserted into
SR-11 Fad·, it was necessary to isolate the cassette for future use as a probe. It was
known that the 1.4 Kbp chloramphenicol resistance gene is flanked by Barn HI
endonuclease restriction sites (21). Therefore, genomic DNA from SR-11 Fad· was
isolated and digested with Barn HI. The vector pBR322, which contains a unique Barn HI
site (Figure 1), was also digested with the endonuclease Barn HI. The cut vector was
then dephosphorylated with calf intestinal alkaline phosphatase (CIAP) to prevent selfligation. A ligase reaction (Figure 2) using a 3:1 insert to vector molar ratio was
performed.
The ligation reaction was electroporated into E. ·coli HBIOI competent cells.
Transformants were selected on Luria agar plates containing chloramphenicol. One of
the chloramphenicol-resistant transformants was isolated and found to be resistant to
ampicillin. The clone was also determined to be sensitive to tetracycline which suggested
an interruption of the tetracycline resistance gene in the vector pBR322 by the
chloramphenicol cassette (Figures 2, 3). The transformant was designated: E. coli HBlOl
(pJHAI ). The plasmid pJHAl was digested with Barn HI and electrophoresed on a 0.9%
agarose gel. Two bands were observed: a band at approximately 4.3 Kbp which
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represents the vector pBR322 and a 1.4 Kbp band corresponding to the chloramphenicol
resistance gene (Figure 4: lane 4). The plasmid pJHAl was also mapped with Eco RI
since the chloramphenicol cassette and the vector pBR322 were known to contain a
unique Eco RI restriction sites (21) (Figure 1). Bands at approximately 4.6 Kbp and 1.2
Kbp (Figure 4: lane 3) confirmed the predicted map of pJHAl (Figure 5).
Southern blot of Salmonella typhimurium SR-11 Fad-. The goal of the

southern hybridization was to determine the sizes of fragments of SR-11 Fad- genomic
DNA containing an intact chloramphenicol cassette. When hybridized to a labeled
chloramphenicol cassette probe, different sized fragments will correspond to different
restriction endonucleases employed to digest the SR-11 Fad- genomic DNA. In order to
reach this goal, the chloramphenicol cassette must be digested with various restriction
endonucleases to determine which enzymes leave the chloramphenicol cassette intact.
Since the plasmid pJHAl now contained the 1.4 Kbp chloramphenicol cassette (Figure 3),
it was mapped with the restriction endonucleases Eco RI, Hind III, Pst I, Pvu II, and Xho

I. Restriction enzymes which left the chloramphenicol cassette intact appeared on an
electrophoresed agarose gel as a singie band: the circular plasmid being cut and linearized
at a unique restriction site in pBR322 (Figure 1), the vector used in constructing pJHAl.
The restriction endonucleases Hind III and Pst I digests of pJHA 1 each revealed a single
band indicating an intact chloramphenicol cassette (Figure 6: lanes 3, 5).
Genomic DNA from Salmonella typhimurium SR-11 Fad- was digested seperately
with Hind III and Pst I, electrophoresed on 0.85% agarose gel, and blotted to a
positively-charged nylon membrane. The membrane was hybridized with the 1.4 Kbp
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chloramphenicol cassette DIG- labeled chemiluminescent probe and developed (see
Materials and Methods). The blot revealed a Hind III fragment of approximately 8.0 Kbp
(Figure 7: lane 6) and a Pst I fragment of approximately 4.2 Kbp (Figure 7: lane 7). The
Hind III fragment should contain approximately 6.6 Kbp of Salmonella typhimurium SR-

11 Fad- genomic DNA flanking the chloramphenicol cassette. Likewise, the Pst I
:fragment should contain approximately 2.8 Kbp of Salmonella typhimurium SR-11 Fadgenomic DNA flanking the chloramphenicol cassette. Equally important, the southern
blot revealed that the virulent parent strain of Salmonella typhimurium SR-11 did not
contain the chloramphenicol cassette (Figure 7: lanes 1, 5), as did the SR-11 Fad- vaccine
candidate strain.

Cloning of the Hind III and Pst I fragments of Salmonella typhimurium SR11 Fad- genomic DNA. Genomic DNA from the SR-11 Fad- strain was isolated and
digested with Hind III or Pst I . The vector pBR322 also was digested with Hind III or
Pst I (Figure 1). Ligase reactions using a 3:1 insert to vector molar ratio were performed

(see Materials and Methods). The ligation reactions were electroporated into E. coli
HB101 competent cells. Transformants were selected on Luria agar plates containing
chloramphenicol.
Plasmid DNA from two of the Hind III chloramphenicol resistant transformants
was isolated, and the clones were characterized. Both clones were determined to be
ampicillin-resistant and tetracycline-resistant. Also, both clones contained plasmids.
These were designated E.coli HB101 (pJHA3) and E.coli HB101 (pJHA4) since they
may or may not have the same Hind III insert orientation.
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Subsequent mapping with the restriction endonuclease Eco RI revealed E. coli
HB101 (pJHA3) as a spontaneous chloramphenicol mutation in the chromosome of E.

coli HBlOl. The clone also contained the insertless, self-ligated vector pBR322. This
insertless vector conferred the observed resistance to ampicillin and tetracycline.
Better results were observed with E.coli HB101 (pJHA4): mapping with Eco RI
revealed three bands greater than 4.0 Kbp. One band represented the pPR322 vector with
its unique Eco RI site (Figures 1). The Eco RI site in the 1.4 Kbp chloramphenicol
resistance gene is 600 hp into the cassette (21). This suggested that fragments of SR-11
Fad- genomic DNA at least 3.2 Kbp in size flanked the chloramphenicol cassette.
However, the flanking genomic DNA was much larger than the ideal 1 Kbp (financial
consideration), and pJHA4 was not sequenced.
Plasmid DNA from two of the Pst I chloramphenicol resistant transformants also
were isolated, and the clones were characterized. Both clones were determined to be
ampicillin-sensitive and tetracycline-resistant. This suggested an interruption of the
ampicillin resistance gene in the vector pBR322 by the chloramphenicol cassette (Figure
1). These clones were designated E. coli HBlOl (pJHA5) and E. coli HB101 (pJHA6)
since they may or may not have the same Pst I insert orientation.
Subsequent mapping of the plasmid pJHA6 with Bam HI, Eco RI, and Pst I
revealed it to be approximately 9.4 Kbp in size. The Eco RI digest of pJHA6 revealed
two bands: approximately 6.9 Kbp and 2.5 Kbp (Figure 8: lane 2). The Pst I digest of
pJHA6 revealed one tall band between approximately 4.2 Kbp and 4.5 Kbp (Figure 9:
lane 3) representing the vector (pBR322 is 4.361 Kbp in size) and the Pst I insert; a
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second band at approximately 600 hp was also observed, but due to its low intensity, is
not visible in the duplicate photograph (Figure 9: lane 3). The Bam HI digest ofpJHA6
showed three bands: approximately 5.7 Kbp, 2.3 Kbp, and a 1.4 Kbp band corresponding
to the chloramphenicol cassette (Figure not shown). Five bands were observed with the
Bam HI-Pst I double digest ofpJHA6 (Figure 9: lane 5): approximately 3.2 Kbp, 1.9

Kbp, 1.4 Kbp, I.I Kbp and 0.6 Kbp (the 0.6 Kbp band is not visible in the duplicate
photograph due to its low intensity). The bands at 1.1 Kbp appear to represent two bands:
one on top of the other. Five bands also were observed with the Eco RI-Pst I double
digest ofpJHA6: approximately 3.6 Kbp, 2.7 Kbp, 1.7 Kbp, 0.8 Kbp and 0.6 Kbp (Figure
8: lane 4). Initially, the 600 hp fragment (a very low intensity band in 0.5% and 0.7%
agarose gels) were puzzling because they were not observed when the plasmid pJHA6
was double digested with Bam HI and Pst I (Figure 9: lane 5). The answer was in the
construction ofpJHA6: the 5.1 Kbp Pst I insert was not isolated from a gel. Instead, SR11 Fad- genomic DNA was digested with Pst I and this digested DNA was used in the
ligation reaction. The Pst I digest of SR-11 Fad- genomic DNA either was incomplete or
the small 600 hp fragment was simply ligated to the end of the fragment containing the
chloramphenicol cassette (Figure 10).
Cloning the 4.5 Kbp Pst I fragment using a sequencing vector. Thirty-six
micrograms of plasmid DNA from E. coli HB 10 I (pJHA6) was isolated, digested with
Pst l, and electrophoresed on a 0. 7% agarose gel. The 4.5 Kbp band was cut from the

gel, purified, and ethanol-precipitated (see Materials and Methods). This removed the
unwanted 600 hp artifact fragment (Figure 10). The 4.5 Kbp fragment (insert) was
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ligated into the multiple cloning site of the cloning vector, pBluescript II SK+
(Stratagene, La Jolla, CA) (Figure 11 ). The ligation reactions were electroporated into E.
coli HB101 competent cells. Transformants were selected on Luria agar plates containing

ampicillin and chloramphenicol. Three of the thousands of transformants were
characterized and plasmid DNA from each was isolated from two of the clones. After
preliminary mapping with Bam HI, Eco RI, and Pst I, one of the clones was designated E.
coliHBlOl (pJHA7).

Plasmid DNA from E. coli HB 101 (pJHA7) was again isolated and digested with
Bam HI, Eco RI, and Pst I. All the digests confirmed the size of the plasmid:

approximately 7.4 Kbp (Figure 12). The Bam HI-Eco RI double digest ofpJHA7 (Figure
12: lane 9) was identical the Bam HI-Eco RI-Pst I triple digest of pJHA7 (Figure 12: lane
10) since they are only several base pairs apart in the multiple cloning site of the
sequencing vector pBluescript II SK+ (Stratagene, La Jolla, CA) (Figurel 1). Both
digests ofpJHA7 revealed five bands: approximately 2.9 Kbp, 2.0 Kbp, 1.1Kbp,0.8 Kbp
and 0.6 Kbp (Figure 12: lanes 9, 10). These double and. triple digests confirmed the
remaining single and double digests ofpJHA7 (Figure 12, lanes 3, 4, 5, 7, 8). The
virulence gene(s) interrupted by the chloramphenicol cassette has been isolated. The
chloramphenicol cassette is flanked by approximately 1.0 Kbp and approximately 1.9
Kbp fragments of Salmonella typhimurium SR-11 Fad· genomic DNA (Figure 13).
Since primers for the T3 and T7 promoter sites (Figures 11, 13) in this sequencing
vector have already been made, this step will facilitate the sequencing of the unknown
gene(s). The plasmid, pJHA7, has been sent out for sequencing.
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Discussion

Salmonella typhimurium SR-11 Fad-, the vaccine candidate, was phenotypically
designated Fad- (Fatty acid) for its inability to metabolize fatty acids as a sole carbon
source (11 ). The SR-11 Fad- strain also is unable to utilize acetate, citrate, and isocitrate
as carbon sources, but can utilize glucose, glycerol, pyruvate, and succinate as sole
carbon sources (11 ). Since SR-11 Fad· can utilize succinate and pyruvate but not citrate
and isocitrate, there appear to be at least two blocks in the tricarboxylic acid cycle (TCA):
one prior to succinate and one in the glyoxylate bypass (11 ). Both blocks result in a
reduction in the synthesis or activity of enzymes within the TCA cycle (11 ). These data
suggest that the mutation is regulatory in nature.
S. typhimurium SR-11 Fad· is a worthy live oral vaccine candidate since it is both

avirulent and immunogenic in BALB/c mice (11) and chickens (Dr. Paul S. Cohen:
personal communication). Since SR-11 Fad- grows on several sugars subject to catabolite
repression, it is not the same live oral vaccine candidate as those based on ~cya
(adenylate cyclase) and ~crp (cyclic 3', 5'-AMP receptor protein) mutations (4, 16).
Furthermore, since SR-11 Fad· grows on glucose supplemented minimal media without
the addition of aromatic compounds, it is not same as live oral vaccine candidates based
on AaroC, AaroD mutations (11 ).
In order for a vaccine to be useful, it must be safe. Therefore it should not contain
antibiotic resistance genes. Since the SR-11 Fad- vaccine candidate was constructed by

TnlOd::cam transposon mutagenesis (11), it contains a chloramphenicol resistance gene.
This chloramphenicol cassette appears to interrupt the expression of a regulatory gene
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necessary for the expression of virulence. The goal of this research was to isolate the
gene(s) interrupted by the chloramphenicol cassette. This virulence gene(s) and the
chloramphenicol resistance cassette could then be permanently deleted yielding a safer
live oral vaccine candidate.
The first step toward that goal was to isolate the chloramphenicol cassette and use
it as a probe in Southern hybridization analysis of genomic DNA. This step revealed the
size of the restriction enzyme-digested DNA fragments containing the chloramphenicol
cassette. The goal was reached when the 4.5 Kbp Pst I-digested fragment was cloned
using the sequencing vector pBluescript II SK+ (Stratagene, La Jolla, CA) (Figures 11,
13). The resulting plasmid, pJHA7, contains 1.0 Kbp and 1.9 Kbp fragments of SR-11
Fad- genomic DNA flanking the chloramphenicol cassette (Figure 13). The flanking
DNA is the virulence gene(s).
The virulence gene(s) in pJHA7 can now be sequenced (22) taking advantage of
primers for the T3 and T7 promoters and the known sequences of the 70 hp inverted
repeats flanking the chloramphenicol cassette (Figure 13). If the results of the sequencing
reveal that the virulence gene(s) lies within a large operon, it may exhibit a polar effect on
downstream genes in the operon (23). If this is the case, then the larger 8.0 Kbp Hind III
fragment in the plasmid pJHA4 can be sub-cloned into the sequencing vector and the
entire operon can be sequenced.
Either fragment of SR-11 Fad- genomic DNA (1.0 Kbp or 1.9 Kbp) in the
plasmid pJHA7 (Figure 13) can now be made into a probe. With this probe, other genera
and species of intracellular bacteria such as Salmonella cholerasuis (swine pathogen),
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Salmonella dub/in (bovine pathogen), Salmonella gallinarum (poultry pathogen),
Escherichia coli, and Yersinia can be screened for virulence gene(s) by Southern
hybridization (19). If they contain the virulence gene(s), then other chloramphenicol
resistant vaccine candidates (easily selected) can be made by homologous recombination
of the 4.5 Kbp Pst I fragment utilizing an allelic exchange vector (24, 25).
Cardenas and Clements (10) noted that, "The use of live attenuated Salmonella
strains as delivery vectors of heterologous antigens to the secretory immune system
constitutes a promising approach for the development of new vaccines against a number
of diseases." It is now recognized that live oral Salmonella vaccines stimulate significant
humoral and secretory antibody responses en route (10). Thus, the SR-11 Fad- vaccine
candidate shows great promise as a delivery vehicle ofheterologous antigens.
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Tables

Table 1. Bacterial strains used in this study.
Strain

Relevant Genotype

Relevant Phenotype

Salmonella typhimurium SR-11

gyrA1816

nalidixic acid resistant

Salmonella typhimurium SR-11 Fad·

gyrA1816

nalidixic acid resistant

TnJOd::cam

chloramphenicol resistant

rpsL20

streptomycin resistant

Escherichia coli HB 101
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Figures

Hind IH(29)

I

Eco RI (4359)
Bam Ill (375)
ampicillin resistance
tetracycline
resistance

pBR322
4361 hp

ori

Figure 1. The unique Ram HI, Eco RI, Hind III, and Pst I restriction enzyme

sites in the cloning vector pBR322. The blue section represents the ampicillin resistance
gene (bla) and the purple section represents the tetracycline resistance gene (tet). The
arrows designate the direction of transcription. The gray arrow depicts the origin and
direction of replication. The numbers in parentheses denote base pairs of DNA.

25

BamHI

1.4 Kbp chloramphenicol
resistance cassette
ampicillin
resistance
Bamm

tetracycline
resistance

pBR322
4361 bp

ori

Figure 2. The construction ofpJHAl. The Bam HI-digested chloramphenicol

cassette (red) was ligated into the unique Bam HI restriction enzyme site in the cloning
vector pBR322. The blue section represents the ampicillin resistance gene (bla) and the
purple section represents the tetracycline resistance gene (tet). The arrows designate the
direction of transcription. The gray arrow depicts the origin and direction of replication.
The numbers in parentheses denote base pairs of DNA.
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tetracycline
resistance
ampicillin
resistance
/

1.4 Kbp chloramphenicol
resistance cassette

pJHAl
-5761 hp

Bam

m (- 1775)

ori

tetracycline
resistance

Figure 3. The interruption of the tetracycline resistance gene (purple) by the 1.4
Kbp chloramphenicol resistance cassette (red) in the plasmid pllIAl. The ampicillin
resistance gene (blue) remains intact. The arrows designate the direction of transcription.
The gray arrow depicts the origin and direction of replication. The numbers in
parentheses, which denote base pairs of DNA, are approximate.
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Lanes:

1

2

3

6.1
5.0

4

_ / .,~~

-

'1-.0

"'"~

3.0
2-0 ·

'·'

""'-+

~L.2..

t.O

Figure4. Agarose(0.9%)gelanalysisoftheplasmidpJHA1. Lane 1: 1 Kbp
ladder; lane 2: Eco RI-digested pBR322; lane 3: Eco RI-digested pJHAl; lane 4: Barn HIdigested pJHA 1.
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tetracycline
/ resistance

Eco RI (5759)
~1200

bp

ampicillin
resistanc

Eco RI

(1175)

1.4 Kbp chloramphenicol
resistance cassette

pJHAl
-5761 hp

Bamm
(1775)

ori
tetracycline
resistance

Figure 5. The plasmid pJHAI mapped with the restriction endonucleases Barn HI
and Eco RI. The tetracycline resistance gene (purple) is interrupted by the
chloramphenicol resistance cassette (red). The ampicillin resistance gene (blue) remains
intact. The arrows in these genes designate the direction of transcription. The gray arrow
(ori) depicts the origin and direction of replication. The numbers in parentheses, which
denote base pairs of DNA, are approximate.
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Lanes:

1

2

3

4

5

6

7

8

9

10

11

~p
\ 2.. 2.

7. 1

s.o
...0

'3.0
".2,.0

'·'
Figure 6. Agarose (0.7%) gel analysis of the plasmid pJHAl revealing the

unique Hind III and Pst I restriction enzyme sites (lanes 3, 5). Lanes 7-11 are control
digests to determine and/or confirm unique restriction endonuclease sites in the vector
pBR322. Unique sites (Lanes 3, 5, 8, 9, 11) are represented by single a band oflinearized
DNA. Lane 1: undigested pJHAl; lane 2: Pvu II-digested pJHAl; lane 3: Hind 111digested pJHAl; lane 4: Xho I-digested pJHAl (either pJHAl does not contain anXho I
restriction site or this was an ineffective digest); lane 5: Pst I-digested pJHAl; lane 6: Eco
RI-digested pJHAl (a band at approximately 1.2 Kbp was also observed, but due to its
low intensity, it is not visible in this duplicate photograph); lane 7: undigested pBR322;
lane 8: Pvu II-digested pBR322; lane 9: Hind III-digested pBR322; lane 10: Xho !digested pBR322 (pBR322 does not contain an Xho I restriction site); lane 11: Pst !digested pBR322.
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Lanes:
23 .l

1

2

3

4

5

6

7

8

-

q.+ _

.-Js.o~b

~. S rv

+.3 -

5 .0 Kb

,...... +.2 l<b

2."3 2.0 I ·~ ~

1.4Kb

{.0 -

Figure 7. Southern hybridization analysis of Salmonella typhimurium SR-11
genomic DNA using the 1.4 Kbp chloramphenicol cassette as a probe. Lane 1: undigested
SR-11 wild-type DNA; lane 2: undigested SR-11 Fad· DNA; lane 3: Barn HI-digested
pJHAl; lane 4: Barn HI-digested SR-11 Fad- DNA; lane 5: Barn HI-digested SR-11 wildtype DNA; lane 6: Hind III-digested SR-11 Fad· DNA; lane 7: Pst I-digested SR-11 Fad·
DNA; lane 8: Eco RI-digested SR-11 Fad· DNA.
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Lanes:

1
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4
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4 .0

4.0
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3.0
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:2. 0

1· S

/. !.)

\.0

1.0

0.1-5

0.15

0.5"0
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Figure 8. Agarose (0.5%) gel analysis of the plasmid pJHA6. Lane 1: 1 Kbp

ladder; lane 2: Eco RI-digested pJHA6; lane 3: Eco RI, Pst I-digested pBR322; lane 4:
Eco RI, Pst I-digested pJHA6; lane 5: 1 Kbp ladder; lane 6: undigested pJHA6; lane 7:
undigested pBR322.
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Lanes: 1

2

3

5 6

4

~

~p
\ 0 .0

\O. O

s.c
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.s.o

e.o

E.. O
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Figure 9. Agarose (0. 7%) gel analysis of the plasmid pJHA6. Lane 1: 1 Kbp
ladder; lane 2: Pst I-digested pBR322 (the band at approximately 1.7 Kbp represents an
irreversibly-denatured form of the vector pBR322); lane 3: Pst I-digested pJHA6 (a band
at approximately 600 bp was also observed, but due to its low intensity, it is not visible in
this duplicate photograph); lane 4: undigested pJHA6; lane 5: Bam HI, Pst I-digested
pJHA6 (a band at approximately 600 bp was also observed, but due to its low intensity, it
is not visible in this duplicate photograph); lane 6: 1 Kbp ladder.
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ampicillin resistanc~

EcoRI (9459)

Pst1 (8706)

(O)

Bam ID(375)
tetracycline resistance

SR-11 Fad- genomic DNA

pJHA6
--9461 bp

1.4 Kbo chloramohenicol
resistance cassette

ori

ampicillin resistance
Pstl(3606)

SR-11 Fad- genomic DNA

Figure 10. The plasmid pJHA6 mapped with the restriction enzymes Bam m,

Eco RI, and Pst I. The ampicillin resistance gene (blue) is interrupted by the 4.5 Kbp Pst

I insert and a 600 bp Pst I artifact. The tetracycline resistance gene (purple) remains
intact. The arrows designate the direction of transcription. The gray arrow depicts the
origin and direction of replication. The numbers in parentheses, which denote base pairs
of DNA, are approximate.

34

(0)

lacZ

pBluescrlpt II SK (+)
2961 bp

c~f

T7 promoter
multiple
cloning site
T3 promoter

El origin

Figure 11. Map of the sequencing vector pBluescript II SK+ (Stratagene, La
Jolla, CA). The multiple cloning site contains the Bam HI, Eco RI, and Pst I restriction
endonuclease sites. The blue arrow represents the ampicillin resistance gene (bla) and its
direction of transcription. Two origins of replication (gray arrows) are included in this
sequencing vector. The lac Z gene is represented by the fuchsia arrow.
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Figure 12. Agarose (0. 7%} gel analysis of the plasmid pJHA7. Lane 1: 1 Kbp
ladder; lane 2: undigested pJHA 7; lane 3: Pst I-digested pJHA 7 (the upper two bands
reveal that this digest was incomplete); lane 4: Eco RI-digested pJHA7; lane 5: Barn HIdigested pJHA 7; lane 6: 1 Kbp ladder; lane 7: Eco RI, Pst I- digested pJHA 7; lane 8: Barn
HI, Pst I-digested pJHA 7 (the upper band at approximately 4 .1 Kbp reveals that this
digest was incomplete); lane 9: Barn HI, Eco RI-digested pJHA7; lane 10: Barn HI, Eco
RI, Pst I-digested pJHA 7; lane 11: 1 Kbp ladder.
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Pstl(O)

BamID(13)

multiple cloning site
T3 promoter
lacZ
co!El origin

SR-11 Fad_
genomic DNA

70 bp from right tenninus
ofTn JOd

pJHA7

Bamm

ampicillin
resistance

-7461 bp

(5461)

fl (+)origin

1.4 Kbp chloramphenicol
resistance cassette
EcoRf (4661)
BamID(4061)
.I

70 bp from right terminus
ofTnJOd

SR-11 Fadgenomic DNA

T7 promoter
multiple cloning site
Eco RI (2954)
Pstl(2961)

Figure 13. The plasmid pJHA7 mapped with the restriction enzymes Ram HI,
Eco RI, and Pst I. The ampicillin resistance gene (blue arrow) remains intact. The

sequences of the T3 and T7 promoters (orange-brown diagonals) and the 70 bp inverted
repeats (orange-brown diagonals) flanking the chloramphenicol cassette (red) are known.
The numbers in parentheses, which denote base pairs of DNA, are approximate.
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